Evidence map›Paper›PMID 28597824›Full record

ReviewMicrobiology spectrum2017

Mycobacterial Biofilms: Revisiting Tuberculosis Bacilli in Extracellular Necrotizing Lesions.

Randall J Basaraba, Anil K Ojha

Abstract readReview
In one paragraph

Review in Microbiology spectrum, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Review
  2. Biofilm Associated Persistence and Drug Tolerance in Mycobacteria Within Host Microenvironments.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026
    Review
  3. Article
  4. Article
  5. Mycobacterial Biofilm: Mechanisms, Clinical Problems, and Treatments.International journal of molecular sciences · 2024
    Review
  6. Article
  7. Biofilm · 2023
    Article
  8. Article
  9. Bacterial biofilms in the human body: prevalence and impacts on health and disease.Frontiers in cellular and infection microbiology · 2023
    Review
  10. Antibiotic Resistance toAntibiotics (Basel, Switzerland) · 2022
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Frontiers in cellular and infection microbiology · 2021
    Article
  17. Review
  18. Review
  19. Molecules (Basel, Switzerland) · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Randall J BasarabaCollege of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Co 80524.
Anil K OjhaWadsworth Center, NY State Department of Health and University at Albany, Albany, NY 12208.

Funding

Alternative Ribosomes & Antibiotic Tolerance in MycobacteriaR01AI132422 · NIAID · WADSWORTH CENTER · PI RAJENDRA K AGRAWAL, Anil Kumar Ojha · 2017 to 2026
$3.8M
NIAID NIH HHS R01 AI132422
6 · The paper itself

Abstract

Under detergent-free

Indexed as

Antitubercular AgentsBiofilmsDrug Resistance, BacterialDrug ToleranceExtracellular SpaceHumansMycobacteriumMycobacterium tuberculosisTuberculosisTuberculosis, PulmonaryAntitubercular Agents

Identifiers

PMID28597824
PMCPMC7875192

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.